Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $8.7700 (-1.46%) ($8.7700 - $8.7700) on Tue. Jan. 26, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.54% (three month average) | RSI | 42 | Latest Price | $8.7700(-1.46%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -0.6% a day on average for past five trading days. | Weekly Trend | AUTL declines -1.9% a week on average for past two weeks. | Market Behavior | Value stocks sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) LIT(13%) SKYY(13%) XBI(13%) BNDX(12%) IBB(12%) | Factors Impacting AUTL price | AUTL will decline at least -2.27% in a week (0% probabilities). TBT(-8%) USO(-7%) VIXM(-6%) IGOV(-6%) UNG(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.27% (StdDev 4.54%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $8.93 | 5 Day Moving Average | $8.74(0.34%) | 10 Day Moving Average | $8.84(-0.79%) | 20 Day Moving Average | $8.93(-1.79%) | To recent high | -26.9% | To recent low | 7.5% | Market Cap | $458m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |